Earnings summaries and quarterly performance for Zymeworks.
Executive leadership at Zymeworks.
Kenneth Galbraith
Detailed
Chief Executive Officer and President
CEO
AS
Adam Schayowitz
Acting Chief Development Officer
JS
Jeffrey Smith
Executive Vice President and Chief Medical Officer
LP
Leone Patterson
Executive Vice President, Chief Business Officer and Chief Financial Officer
PM
Paul Moore
Chief Scientific Officer
Board of directors at Zymeworks.
Research analysts who have asked questions during Zymeworks earnings calls.
SW
Stephen Willey
Stifel Financial Corp.
4 questions for ZYME
Also covers: ABCL, CELC, CGEN +10 more
YN
Yigal Nochomovitz
Citigroup Inc.
4 questions for ZYME
Also covers: ALDX, APLS, ARCT +22 more
BC
Brian Cheng
JPMorgan Chase & Co.
3 questions for ZYME
Also covers: ALLO, CHRS, EDIT +6 more
Derek Archila
Wells Fargo
3 questions for ZYME
Also covers: APLS, ARGX, ARVN +9 more
Akash Tewari
Jefferies
2 questions for ZYME
Also covers: ALKS, APLS, ARGX +15 more
JM
John Miller
Evercore ISI
2 questions for ZYME
Also covers: MGNX
Jonathan Miller
Evercore ISI
2 questions for ZYME
Also covers: APLS, ARVN, ATRA +8 more
Amanda Acosta-Ruiz
Leerink Partners
1 question for ZYME
Also covers: ARVN
CZ
Charles Zhu
LifeSci Capital, LLC
1 question for ZYME
Also covers: IDYA, KURA, MRSN +2 more
Emily Shutman
Leerink Partners
1 question for ZYME
Jay Olson
Oppenheimer & Co. Inc.
1 question for ZYME
Also covers: ACAD, AMGN, BIIB +22 more
Justin Zelin
BTIG, LLC
1 question for ZYME
Also covers: BCAB, CASI, GLMD +9 more
LM
Lut Ming Cheng
JPMorgan Chase & Co.
1 question for ZYME
Also covers: ALLO, CHRS, EDIT +3 more
Manoj Eradath
Jefferies LLC
1 question for ZYME
Also covers: BNTX
Mayank Mamtani
B. Riley Securities
1 question for ZYME
Also covers: AGEN, ALT, ARWR +18 more
PT
Phoebe Tan
Jefferies Financial Group Inc.
1 question for ZYME
Also covers: CYTK, NBIX
Robert Burns
H.C. Wainwright & Co.
1 question for ZYME
Also covers: ALLO, CRDF, YMAB
YW
Yaron Werber
TD Cowen
1 question for ZYME
Also covers: ALEC, AMGN, ARGX +14 more
YZ
Yue-Wen Zhu
LifeSci Capital
1 question for ZYME
Also covers: KURA, MRSN
Recent press releases and 8-K filings for ZYME.
Zymeworks Discusses Zanidatamab Success and Evolving Strategy at J.P. Morgan Conference
ZYME
Product Launch
New Projects/Investments
Guidance Update
- Zymeworks announced positive results from the HERIZON-GEA-01 study for zanidatamab, which is expected to become the new standard of care for HER2-overexpressing GEA, potentially replacing Herceptin.
- The company is evolving its strategy to combine its innovative R&D efforts with leveraging significant royalty and milestone streams from successful agents like zanidatamab and pasritamig, a Phase III asset with J&J estimated to have a $1-$5 billion peak sales potential.
- Zymeworks reported a strong financial position with a cash runway extending beyond 2028, anticipating an "excess cash flow problem" from future milestone payments related to zanidatamab's BLA approval.
5 hours ago
Zymeworks CEO Discusses Transformative Year and Evolving Strategy
ZYME
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Zymeworks' CEO Ken Galbraith highlighted a "transformative year" driven by the Horizon-GEA-01 study readout for zanidatamab, which is anticipated to become the new standard of care in HER2-overexpressing GEA.
- The company is shifting its strategy to blend innovative R&D with leveraging royalty and milestone streams from key assets, including zanidatamab and JNJ-64264681, which J&J projects could achieve $1-$5 billion in peak sales.
- Zymeworks reported a strong financial position with a cash runway extending beyond 2028, expecting future "excess cash flow" from upcoming milestones and royalties.
- The Horizon-GEA-01 data indicated zanidatamab is a superior HER2-targeted agent to trastuzumab, with the triplet regimen demonstrating an "unheard of" median Duration of Response of almost 21 months in the GEA patient population.
6 hours ago
Zymeworks Discusses Transformative Year and Evolving Strategy at J.P. Morgan Healthcare Conference
ZYME
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
- Zymeworks experienced a transformative year, marked by the readout of the Horizon-GEA-01 study for zanidatamab, which is anticipated to become the new standard of care in the HER2-overexpressing GEA population.
- The company is evolving its strategy to leverage the value from royalties and milestone streams expected from zanidatamab and other agents like JNJ-64264681 (currently in Phase 3 trials), while continuing to operate as an innovative R&D company.
- Zymeworks is in a strong financial position, with a cash runway projected to extend beyond 2028, and foresees a potential "excess cash flow problem" in the future.
- The company maintains a differentiated pipeline of wholly-owned clinical and preclinical assets, with new data expected for its folate receptor alpha ADC in 2026 and a recently initiated Phase 1 study for its GPC3 ADC.
6 hours ago
Zymeworks Outlines 2026 Strategic Priorities, Financial Outlook, and Leadership Changes
ZYME
Guidance Update
Share Buyback
CFO Change
- Zymeworks reported approximately $270.6 million in cash, cash equivalents, and marketable securities as of December 31, 2025, and expects a cash runway beyond 2028, assuming full execution of a $125.0 million share repurchase plan and receipt of $440.0 million in anticipated regulatory milestone payments for Ziihera.
- The company announced positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive gastroesophageal adenocarcinoma (GEA), with partner Jazz Pharmaceuticals planning a supplemental Biologics License Application submission in 1H-2026 in the U.S..
- Zymeworks outlined a new strategy focused on integrating royalty growth, strategic acquisitions, and internal R&D innovation. Concurrently, Leone Patterson was terminated as Chief Financial Officer effective January 9, 2026, with Kenneth Galbraith assuming the role of Acting CFO, and Brian Cherry was appointed to the Board of Directors effective January 12, 2026.
2 days ago
Boehringer Ingelheim and Jazz Pharmaceuticals Announce Clinical Collaboration
ZYME
New Projects/Investments
- Boehringer Ingelheim and Jazz Pharmaceuticals have established a strategic clinical collaboration to develop a novel combination therapy for HER2-positive breast cancer.
- The collaboration will initiate a Phase 1b cohort within Boehringer’s Beamion-BCGC1 trial, evaluating the combination of Boehringer’s zongertinib and Jazz’s zanidatamab.
- Zongertinib (HERNEXEOS®) recently received accelerated FDA approval for HER2-mutant advanced non-small cell lung cancer.
- Zanidatamab (ZIIHERA®) received accelerated FDA approval for HER2-positive biliary tract cancer and is currently in Phase III trials for metastatic breast cancer.
3 days ago
Zymeworks Outlines 2026 Strategic Priorities and Financial Outlook
ZYME
Guidance Update
Share Buyback
New Projects/Investments
- Zymeworks reported positive Phase 3 HERIZON-GEA-01 results for Ziihera in first-line HER2-positive gastroesophageal adenocarcinoma (GEA) and expects to earn up to $440.0 million in milestone payments from its regulatory approvals in the U.S., Europe, Japan, and China.
- The company held approximately $270.6 million (unaudited) in cash, cash equivalents, and marketable securities as of December 31, 2025, and anticipates this, along with Ziihera milestone payments, will provide a cash runway beyond 2028.
- A $125.0 million share repurchase plan was authorized in November 2025, with $19.0 million already utilized to repurchase 727,271 shares at an average price of $26.07.
- Zymeworks is executing a new strategy to compound long-term value by integrating royalty growth, strategic acquisitions, and continued internal R&D innovation.
3 days ago
Zymeworks' ZIIHERA Combination Therapy Shows Positive Phase 3 Results for HER2+ GEA
ZYME
Product Launch
New Projects/Investments
- BeOne Medicines announced positive full results from the Phase 3 HERIZON-GEA-01 trial for ZIIHERA (zanidatamab), a HER2-targeted bispecific antibody licensed from Zymeworks, in combination with chemotherapy, with and without TEVIMBRA, for first-line HER2-positive advanced gastroesophageal adenocarcinoma (GEA).
- The combination of ZIIHERA plus TEVIMBRA and chemotherapy achieved a median overall survival (OS) of 26.4 months, representing a 28% reduction in the risk of death compared to the control arm.
- This regimen also demonstrated a 37% reduction in the risk of disease progression and a greater than 4-month improvement in median progression-free survival (mPFS).
- BeOne intends to submit supplemental Biologics License Applications to the U.S. FDA for TEVIMBRA and to the CDE of China's NMPA for TEVIMBRA and ZIIHERA based on these data.
Jan 6, 2026, 6:30 PM
Zymeworks Outlines Evolved Business Strategy and Capital Allocation
ZYME
New Projects/Investments
Share Buyback
Guidance Update
- Zymeworks has evolved its business strategy since 2022, focusing on leveraging its IP and R&D capabilities to generate value through royalty streams and partnerships rather than building a commercial organization.
- The company anticipates excess capital following HERIZON-GEA-01 data, which will be allocated to drive shareholder value, including potential share buybacks and investments in both internal and external R&D and royalty assets.
- Zymeworks holds a strong financial interest in Zymeworks (partnered with Jazz) and Rybrevant, which J&J guides for $1 billion-$5 billion peak sales.
- The wholly-owned portfolio includes ZW191 (folate receptor alpha ADC) with strong early data, for which a partnership strategy is being considered before pivotal studies, and ZW251 (HCC) in clinical development.
Dec 2, 2025, 3:00 PM
Zymeworks Discusses Evolving Business Strategy and Pipeline at HealthCONx Conference
ZYME
New Projects/Investments
M&A
Revenue Acceleration/Inflection
- Zymeworks is evolving its business strategy to focus on generating cash flows from a royalty portfolio (including Zymeworks and Rybrevant) while maintaining an innovative R&D organization.
- The company utilized a $375 million upfront payment from its partnership with Jazz to build a wholly-owned R&D portfolio, featuring lead ADC assets such as ZW191 and ZW251.
- ZW191, a folate receptor alpha ADC, demonstrated rapid development, moving from first patient dose to first data disclosure in 11 months, and the company is considering a partnership for this asset before a pivotal study.
- Zymeworks views its integrated R&D and royalty organization as a unique competitive advantage, enabling flexible capital allocation, including potential share buybacks, and the ability to acquire external assets for both royalties and R&D.
- The company anticipates significant value from its royalty assets, with Rybrevant guided by J&J as a $1 billion-$5 billion peak sales opportunity.
Dec 2, 2025, 3:00 PM
Zymeworks Announces Positive Clinical Data and Strategic Shift Towards Royalty Aggregation
ZYME
New Projects/Investments
Share Buyback
Revenue Acceleration/Inflection
- Zymeworks announced positive top-line data from the pivotal HERIZON-GEA-01 clinical trials for its zanidatamab, which, along with pasritamig, is advancing into registration studies.
- The company has achieved $500 million in upfront and development milestones for Ziihera (zanidatamab) and expects approximately $1.5 billion in additional potential milestones, including $440 million in the near term for anticipated global regulatory approvals for GEA.
- Zymeworks is eligible for 10%-20% tiered royalties on Ziihera sales, with Jazz projecting $2 billion-plus peak sales, and also anticipates $434 million in future milestones and mid-single-digit royalties from pasritamig, which J&J guided to potential peak annual sales between $1 million and $5 million.
- The company is transforming its strategy from a traditional high-risk biotech to a revenue-generating organization, focusing on R&D innovation, strategic partnerships, and a royalty aggregation platform to drive growth and returns.
- Financially, Zymeworks reported $103 million in revenues for 2025 as of September 30, holds almost $300 million in cash, and authorized a new $125 million share buyback, building on $60 million in repurchases during 2024 and 2025.
Nov 18, 2025, 1:30 PM
Quarterly earnings call transcripts for Zymeworks.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more